CEO Marc Voigt said: “We are very excited to be working alongside CYTLIMIC to help evaluate efti as part of an innovative cancer vaccine that has potential as a new therapy.
Efti is generating interest globally. Following the agreements with CYTLIMIC, it is now being evaluated as part of three different combination therapy types: as part of a therapeutic cancer vaccine, as a chemo-immunotherapy and in an IO combination, showing its broad therapeutic potential.”
CEO Marc Voigt said: “We are very excited to be working...
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
0.025(8.20%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 33.0¢ | 30.5¢ | $1.720M | 5.352M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29508 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 152875 | 3 |
View Market Depth
| Last trade - 16.10pm 25/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
